{"id":53266,"date":"2023-01-25T07:02:04","date_gmt":"2023-01-25T06:02:04","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/innate-pharma-announces-hsr-clearance-regarding-expansion-of-its-collaboration-with-sanofi-on-nk-cell-engagers\/"},"modified":"2023-01-25T07:02:04","modified_gmt":"2023-01-25T06:02:04","slug":"innate-pharma-announces-hsr-clearance-regarding-expansion-of-its-collaboration-with-sanofi-on-nk-cell-engagers","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/innate-pharma-announces-hsr-clearance-regarding-expansion-of-its-collaboration-with-sanofi-on-nk-cell-engagers\/","title":{"rendered":"Innate Pharma Announces HSR Clearance Regarding Expansion of Its Collaboration With Sanofi on NK Cell Engagers"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\n<b><i>Following expiration of Hart-Scott-Rodino waiting period regarding expansion of their collaboration on NK cell engagers, the licensing agreement between Sanofi and Innate is now effective.<\/i><\/b>\n<\/li>\n<\/ul>\n<p>MARSEILLE, France&#8211;(BUSINESS WIRE)&#8211;<a href=\"https:\/\/twitter.com\/hashtag\/ANKET?src=hash\" target=\"_blank\" rel=\"noopener\">#ANKET<\/a>&#8211;Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201c<strong>Innate<\/strong>\u201d or the \u201c<strong>Company<\/strong>\u201d) announced today the expiration of the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976 with respect to the <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.innate-pharma.com%2Fnode%2F3178%2F&amp;esheet=53289813&amp;newsitemid=20230124005597&amp;lan=en-US&amp;anchor=previously+announced&amp;index=1&amp;md5=c9e26ecd7aae2c21a15c15064df72e8c\" rel=\"nofollow noopener\" shape=\"rect\">previously announced<\/a> expansion of its collaboration with Sanofi. The licensing agreement is now effective.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20230124005597\/en\/1245155\/4\/INNATEvertnoirDS.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230124005597\/en\/1245155\/21\/INNATEvertnoirDS.jpg\"><\/a><\/p>\n<p>\nAs announced on December 19, 2022, Sanofi is licensing a Natural Killer (NK) cell engager program targeting B7H3 from Innate\u2019s ANKET<sup>\u00ae<\/sup> (<b>A<\/b>ntibody-based <b>NK<\/b> Cell <b>E<\/b>ngager <b>T<\/b>herapeutics) platform. Sanofi will also have the option to add up to two additional ANKET<sup>\u00ae<\/sup> targets. Upon candidate selection, Sanofi will be responsible for all development, manufacturing and commercialization. Under the terms of the agreement, Innate will receive \u20ac25m upfront payment and up to \u20ac1.35bn total in preclinical, clinical, regulatory and commercial milestones plus royalties on potential net sales.\n<\/p>\n<p>\n<b>About ANKET<sup>\u00ae<\/sup><\/b>\n<\/p>\n<p>\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.innate-pharma.com%2Fscience%2Four-nk-cell-engager-platform&amp;esheet=53289813&amp;newsitemid=20230124005597&amp;lan=en-US&amp;anchor=ANKET%26%23174%3B&amp;index=2&amp;md5=add7041753bb2a2d1b3c2002523bdccc\" rel=\"nofollow noopener\" shape=\"rect\">ANKET<sup>\u00ae<\/sup><\/a> (Antibody-based NK cell Engager Therapeutics) is Innate&#8217;s proprietary platform for developing next-generation, multi-specific natural killer (NK) cell engagers to treat certain types of cancer.\n<\/p>\n<p>\nThis versatile, fit-for-purpose technology is creating an entirely new class of molecules to induce synthetic immunity against cancer. It leverages the advantages of harnessing NK cell effector functions against cancer cells and also provides proliferation and activation signals targeted to NK cells.\n<\/p>\n<p>\nOur latest innovation, the tetra-specific ANKET molecule, is the first NK cell engager technology to engage activating receptors (NKp46 and CD16), a tumor antigen and an interleukin-2 receptor (via an IL-2 variant, IL-2v) via a single molecule.\n<\/p>\n<p>\n<b>About Innate Pharma<\/b>\n<\/p>\n<p>\nInnate Pharma S.A. is a global, clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.\n<\/p>\n<p>\nInnate Pharma\u2019s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.\n<\/p>\n<p>\nInnate is a pioneer in the understanding of Natural Killer cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A\/S, Sanofi, and a multi-products collaboration with AstraZeneca.\n<\/p>\n<div class=\"bwpagebreakafter\">\n<\/div>\n<p>\nHeadquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.\n<\/p>\n<p>\nLearn more about Innate Pharma at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.innate-pharma.com&amp;esheet=53289813&amp;newsitemid=20230124005597&amp;lan=en-US&amp;anchor=www.innate-pharma.com&amp;index=3&amp;md5=bd6b5d243657a8996564eee18a65f522\" rel=\"nofollow noopener\" shape=\"rect\">www.innate-pharma.com<\/a>\n<\/p>\n<p>\n<b>Information about Innate Pharma shares:<\/b>\n<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignl bwcellpmargin\">\n<b>ISIN code<\/b><br \/><b>Ticker code<\/b><br \/><b>LEI<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nFR0010331421\n<\/p>\n<p class=\"bwcellpmargin\">\nEuronext: IPH Nasdaq: IPHA\n<\/p>\n<p class=\"bwcellpmargin\">\n9695002Y8420ZB8HJE29\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\n<b>Disclaimer on forward-looking information and risk factors:<\/b>\n<\/p>\n<p>\nThis press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including \u201cbelieve,\u201d \u201cpotential,\u201d \u201cexpect\u201d and \u201cwill\u201d and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company\u2019s commercialization efforts, the Company\u2019s continued ability to raise capital to fund its development and the overall impact of the COVID-19 outbreak on the global healthcare system as well as the Company\u2019s business, financial condition and results of operations. For an additional discussion of risks and uncertainties which could cause the company&#8217;s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (\u201cFacteurs de Risque&#8221;) section of the Universal Registration Document filed with the French Financial Markets Authority (\u201cAMF\u201d), which is available on the AMF website <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.amf-france.org&amp;esheet=53289813&amp;newsitemid=20230124005597&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.amf-france.org&amp;index=4&amp;md5=9af2770115436e07f65436f516a4d97a\" rel=\"nofollow noopener\" shape=\"rect\">http:\/\/www.amf-france.org<\/a> or on Innate Pharma\u2019s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (\u201cSEC\u201d), including the Company\u2019s Annual Report on Form 20-F for the year ended December 31, 2021, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company.\n<\/p>\n<p>\nThis press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p><b><span class=\"bwuline\">Investors<\/span><\/b>\n<\/p>\n<p>\n<b>Innate Pharma<\/b><br \/>Henry Wheeler<br \/>\n<br \/>Tel.: +33 (0)4 84 90 32 88<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;&#x69;l&#116;&#x6f;:&#72;&#x65;n&#114;&#x79;&#46;&#119;&#x68;&#x65;&#101;&#x6c;&#x65;r&#64;&#x69;n&#110;&#x61;t&#101;&#x2d;&#x70;&#104;&#x61;&#x72;m&#97;&#x2e;f&#114;\" rel=\"nofollow noopener\" shape=\"rect\">&#72;&#x65;&#110;&#x72;&#121;&#x2e;&#119;&#x68;e&#x65;l&#x65;r&#x40;i&#110;&#x6e;&#97;&#x74;&#101;&#x2d;&#112;&#x68;&#97;&#x72;m&#x61;&#46;&#x66;r<\/a>\n<\/p>\n<p>\n<b><span class=\"bwuline\">Media Relations<\/span><\/b>\n<\/p>\n<p>\n<b>NewCap<\/b><br \/>Arthur Rouill\u00e9<br \/>\n<br \/>Tel.: +33 (0)1 44 71 00 15<br \/>\n<br \/><a target=\"_blank\" href=\"m&#97;&#x69;&#x6c;t&#111;&#58;&#x69;&#x6e;n&#97;&#x74;&#x65;&#64;&#110;&#101;&#x77;&#x63;a&#112;&#x2e;&#x65;u\" rel=\"nofollow noopener\" shape=\"rect\">&#105;n&#x6e;a&#x74;&#101;&#x40;&#110;&#x65;&#119;c&#x61;p&#x2e;&#101;&#x75;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Following expiration of Hart-Scott-Rodino waiting period regarding expansion of their collaboration on NK cell engagers, the licensing agreement between Sanofi and Innate is now effective. MARSEILLE, France&#8211;(BUSINESS WIRE)&#8211;#ANKET&#8211;Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201cInnate\u201d or the \u201cCompany\u201d) announced today the expiration of the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/innate-pharma-announces-hsr-clearance-regarding-expansion-of-its-collaboration-with-sanofi-on-nk-cell-engagers\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-53266","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Innate Pharma Announces HSR Clearance Regarding Expansion of Its Collaboration With Sanofi on NK Cell Engagers - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/innate-pharma-announces-hsr-clearance-regarding-expansion-of-its-collaboration-with-sanofi-on-nk-cell-engagers\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Innate Pharma Announces HSR Clearance Regarding Expansion of Its Collaboration With Sanofi on NK Cell Engagers - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Following expiration of Hart-Scott-Rodino waiting period regarding expansion of their collaboration on NK cell engagers, the licensing agreement between Sanofi and Innate is now effective. MARSEILLE, France&#8211;(BUSINESS WIRE)&#8211;#ANKET&#8211;Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201cInnate\u201d or the \u201cCompany\u201d) announced today the expiration of the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/innate-pharma-announces-hsr-clearance-regarding-expansion-of-its-collaboration-with-sanofi-on-nk-cell-engagers\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-25T06:02:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230124005597\/en\/1245155\/21\/INNATEvertnoirDS.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-announces-hsr-clearance-regarding-expansion-of-its-collaboration-with-sanofi-on-nk-cell-engagers\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-announces-hsr-clearance-regarding-expansion-of-its-collaboration-with-sanofi-on-nk-cell-engagers\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Innate Pharma Announces HSR Clearance Regarding Expansion of Its Collaboration With Sanofi on NK Cell Engagers\",\"datePublished\":\"2023-01-25T06:02:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-announces-hsr-clearance-regarding-expansion-of-its-collaboration-with-sanofi-on-nk-cell-engagers\\\/\"},\"wordCount\":786,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-announces-hsr-clearance-regarding-expansion-of-its-collaboration-with-sanofi-on-nk-cell-engagers\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230124005597\\\/en\\\/1245155\\\/21\\\/INNATEvertnoirDS.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-announces-hsr-clearance-regarding-expansion-of-its-collaboration-with-sanofi-on-nk-cell-engagers\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-announces-hsr-clearance-regarding-expansion-of-its-collaboration-with-sanofi-on-nk-cell-engagers\\\/\",\"name\":\"Innate Pharma Announces HSR Clearance Regarding Expansion of Its Collaboration With Sanofi on NK Cell Engagers - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-announces-hsr-clearance-regarding-expansion-of-its-collaboration-with-sanofi-on-nk-cell-engagers\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-announces-hsr-clearance-regarding-expansion-of-its-collaboration-with-sanofi-on-nk-cell-engagers\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230124005597\\\/en\\\/1245155\\\/21\\\/INNATEvertnoirDS.jpg\",\"datePublished\":\"2023-01-25T06:02:04+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-announces-hsr-clearance-regarding-expansion-of-its-collaboration-with-sanofi-on-nk-cell-engagers\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-announces-hsr-clearance-regarding-expansion-of-its-collaboration-with-sanofi-on-nk-cell-engagers\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-announces-hsr-clearance-regarding-expansion-of-its-collaboration-with-sanofi-on-nk-cell-engagers\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230124005597\\\/en\\\/1245155\\\/21\\\/INNATEvertnoirDS.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230124005597\\\/en\\\/1245155\\\/21\\\/INNATEvertnoirDS.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-announces-hsr-clearance-regarding-expansion-of-its-collaboration-with-sanofi-on-nk-cell-engagers\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Innate Pharma Announces HSR Clearance Regarding Expansion of Its Collaboration With Sanofi on NK Cell Engagers\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Innate Pharma Announces HSR Clearance Regarding Expansion of Its Collaboration With Sanofi on NK Cell Engagers - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/innate-pharma-announces-hsr-clearance-regarding-expansion-of-its-collaboration-with-sanofi-on-nk-cell-engagers\/","og_locale":"en_US","og_type":"article","og_title":"Innate Pharma Announces HSR Clearance Regarding Expansion of Its Collaboration With Sanofi on NK Cell Engagers - Pharma Trend","og_description":"Following expiration of Hart-Scott-Rodino waiting period regarding expansion of their collaboration on NK cell engagers, the licensing agreement between Sanofi and Innate is now effective. MARSEILLE, France&#8211;(BUSINESS WIRE)&#8211;#ANKET&#8211;Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201cInnate\u201d or the \u201cCompany\u201d) announced today the expiration of the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/innate-pharma-announces-hsr-clearance-regarding-expansion-of-its-collaboration-with-sanofi-on-nk-cell-engagers\/","og_site_name":"Pharma Trend","article_published_time":"2023-01-25T06:02:04+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230124005597\/en\/1245155\/21\/INNATEvertnoirDS.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-announces-hsr-clearance-regarding-expansion-of-its-collaboration-with-sanofi-on-nk-cell-engagers\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-announces-hsr-clearance-regarding-expansion-of-its-collaboration-with-sanofi-on-nk-cell-engagers\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Innate Pharma Announces HSR Clearance Regarding Expansion of Its Collaboration With Sanofi on NK Cell Engagers","datePublished":"2023-01-25T06:02:04+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-announces-hsr-clearance-regarding-expansion-of-its-collaboration-with-sanofi-on-nk-cell-engagers\/"},"wordCount":786,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-announces-hsr-clearance-regarding-expansion-of-its-collaboration-with-sanofi-on-nk-cell-engagers\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230124005597\/en\/1245155\/21\/INNATEvertnoirDS.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-announces-hsr-clearance-regarding-expansion-of-its-collaboration-with-sanofi-on-nk-cell-engagers\/","url":"https:\/\/pharma-trend.com\/en\/innate-pharma-announces-hsr-clearance-regarding-expansion-of-its-collaboration-with-sanofi-on-nk-cell-engagers\/","name":"Innate Pharma Announces HSR Clearance Regarding Expansion of Its Collaboration With Sanofi on NK Cell Engagers - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-announces-hsr-clearance-regarding-expansion-of-its-collaboration-with-sanofi-on-nk-cell-engagers\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-announces-hsr-clearance-regarding-expansion-of-its-collaboration-with-sanofi-on-nk-cell-engagers\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230124005597\/en\/1245155\/21\/INNATEvertnoirDS.jpg","datePublished":"2023-01-25T06:02:04+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-announces-hsr-clearance-regarding-expansion-of-its-collaboration-with-sanofi-on-nk-cell-engagers\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/innate-pharma-announces-hsr-clearance-regarding-expansion-of-its-collaboration-with-sanofi-on-nk-cell-engagers\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-announces-hsr-clearance-regarding-expansion-of-its-collaboration-with-sanofi-on-nk-cell-engagers\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230124005597\/en\/1245155\/21\/INNATEvertnoirDS.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230124005597\/en\/1245155\/21\/INNATEvertnoirDS.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-announces-hsr-clearance-regarding-expansion-of-its-collaboration-with-sanofi-on-nk-cell-engagers\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Innate Pharma Announces HSR Clearance Regarding Expansion of Its Collaboration With Sanofi on NK Cell Engagers"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53266","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=53266"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53266\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=53266"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=53266"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=53266"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}